Famitinib plus immunotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can do daily activities on your own (ECOG score 0–1).
- You have advanced or metastatic triple-negative breast cancer confirmed by lab tests (no ER, no PR, and no HER2).
- Your cancer must be measurable on scans and you have not had chemotherapy or targeted therapy for metastatic triple-negative breast cancer yet.
- You must have generally healthy blood counts and major organ function based on recent lab tests.
- You must not have had prior VEGFR “anti-angiogenesis” pills like famitinib, sorafenib, sunitinib, or regorafenib for this cancer.
- You can’t have certain bleeding/clotting risks, active infections (HIV, hepatitis B/C), untreated uncontrolled fluid around the lungs/abdomen, or known brain (CNS) disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
This trial tests a combination of two drugs, camrelizumab and famitinib, given after surgery to remove cervical cancer. The goal is to see if this treatment can help prevent the cancer from coming back.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.